- Tytuł:
- HTA4 Pembrolizumab Vs. Standard of Care Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer with High Pd-L1 Expression Levels: A Cost-Utility Analysis from the Ontario, Canada Public Payer Perspective
- Autorzy:
- Źródło:
- In Value in Health June 2023 26(6) Supplement:S259-S259
Czasopismo naukowe